

LSE SPARK WORKSHOP:

Solutions for Life Sciences Entrepreneurship

July 29, 2022

Overview

The life sciences industry in the United States is at a crossroads. On the one hand, the industry faces boundless opportunities for improving health care outcomes and services. On the other hand, commercialization of scientific advancements has proven to be challenging, creating significant underutilization of societal resources. Entrepreneurship in established corporations and newly spawned entities offers a critical piece of the puzzle to address this problem.

This workshop brings together a diverse set of innovators and strategic thinkers in entrepreneurial, investment, and governmental spaces to stimulate ongoing thought leadership to address these concerns. The event will explore emerging research and entrepreneurial opportunities in the life sciences sector, and the commercialization constraints entrepreneurs face as they attempt to find viable paths to market, among other pertinent issues. The event will be held on the Rensselaer Polytechnic Institute campus, which has a rich tradition of cutting-edge research and innovation in the life sciences.

Agenda

11:30 a.m.

ARRIVAL AND CHECK-IN

12:00-12:45 p.m.

LUNCH

12:45-1:30 p.m.

WELCOME, OPENING REMARKS, AND KEYNOTE ADDRESS

Focus: “Key Success Factors in Life Sciences Entrepreneurship”

Speaker: Rensselaer Trustee Roy N. Davis '78, former President of Johnson & Johnson Development Corporation

1:30-2:00 p.m.

PRESENTATION AND DISCUSSION ON “CEPM-ENGINEERING THE FUTURE OF MEDICINE”

Focus: Research and Center for Engineering and Precision Medicine

Speaker: Deepak Vashishth, Ph.D., Director, Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies, and Professor of Biomedical Engineering

2:00-2:15 p.m.

COFFEE BREAK

2:15-3:00 p.m.

PANEL DISCUSSION ON “LIFE SCIENCES DEAL FLOW: SOLUTIONS TO OPEN THE PIPELINE”

Focus: Investment

Panel Moderator: Shreefal Mehta, Ph.D., Chief Commercial Officer, KAYA17

Panel Members: Clayton Besch III, Ph.D. (Director, NYS Innovation Venture Capital Fund); Noa Conger Simons (CEO, Upstate Capital Association of New York); Jon Gordon (Founder and Managing Partner, HC9 Ventures)

Agenda

3:00-4:00 p.m.

PANEL DISCUSSION ON “CONNECTING NODES: ACCELERATING INNOVATION IN LIFE SCIENCES”

Focus: Leveraging Ecosystems

Panel Moderator: Brian Nickerson, Ph.D., Senior Associate Dean, Icahn School of Medicine at Mount Sinai

Panel Members: Joseph Borrello (BioDesign Lead, Mount Sinai); Craig Cook (Secretary of the Institute and General Counsel, Rensselaer); Eric Ledet, Ph.D. (Chief Science Officer, ReVivo Medical); Tyree Williams (BioDesign Team, Rensselaer)

4:00-4:15 p.m.

COFFEE BREAK

4:15-5:15 p.m.

PANEL DISCUSSION ON “PROBLEMS TO SOLUTIONS: THE ENTREPRENEURIAL PROCESS AND NAVIGATING COMPLEX SCIENTIFIC MARKETS”

Focus: Commercialization

Panel Moderator: Jason Kuruzovich, Ph.D., Director, Severino Center for Technological Entrepreneurship and Associate Professor, Lally School of Management

Panel Members: Marc Eigner '97 (Executive Partner, Berenson & Company); Meghan Olson '15, M.S. '15 (Manager, Ecovative); Sally Temple, Ph.D. (Cofounder and Scientific Director, Neural Stem Cell Institute); Jesse Treu '68, Ph.D. (Founding Partner, Domain Associates)

5:15-5:30 p.m.

CLOSING REMARKS

Brett Orzechowski, Life Sciences Entrepreneurship Program, Lally School of Management

5:30 p.m.

COFFEE AND DESSERT RECEPTION

Keynote Address




“Key Success Factors in Life Science Entrepreneurship”

Overview: The address will outline what approaches have proven successful in shaping life science innovations into successful endeavors that create value for society, patients, and investors. The slant will be toward innovations that are useful in the medical field and toward commercial business success. Life sciences research and development applied to medicine has the potential for great rewards, but also comes with unique hurdles, risks, and cost structures that require the entrepreneur to actively manage in order to be successful. This talk will examine these key factors and offer general guidance to those in the field.

Duration: 30 minutes (1:00-1:30 p.m.)

Keynote Speaker Bio

“Key Success Factors in Life Science Entrepreneurship”



Roy N. Davis '78

**Former President, Johnson & Johnson Development Corporation
Trustee, Rensselaer Polytechnic Institute**

Roy N. Davis served as president of Johnson & Johnson Development Corporation and as corporate vice president of business development for all of Johnson & Johnson (J&J) from January 2008 until his retirement in January 2012. In these roles, he was responsible for helping J&J to determine its new business creation and acquisition strategy and its venture investment portfolio as a global corporation. Davis was the leader of the J&J wholly owned ventures group as well as the creator of Red Script Ventures, LLC, J&J's business accelerator.

From September 2003 through December 2007, Davis held the concurrent positions of company group chairman, J&J, and worldwide franchise chairman, diagnostics. He was a member of J&J's Medical Devices & Diagnostics Group Operating Committee, which oversees one of the world's largest medical device businesses with over \$25 billion in revenue and over 40,000 employees.

Prior to being named company group chairman, Davis founded Veridex, LLC, a new company within J&J that produced award-winning products for cancer diagnostics. Earlier in his career, he served as managing director of J&J Northern Europe and in 1990 was named president of J&J Japan.

Following his retirement, Davis served as a member of the Innovations Advisory Board for the Cleveland Clinic and the Advisory Board for the Wake Forest Institute for Regenerative Medicine. He has been an adviser to Innosight Consulting since March of 2012 and to its parent company, Huron Consulting, since October 2017. He is also an adviser and board member for Clinical Genomics. Davis received a bachelor's degree from the State University of New York at Albany, and a master's degree from Rensselaer Polytechnic Institute in 1978.

Presentation and Discussion

“CEPM-Engineering the Future of Medicine”

Overview: There is a need to provide a new angle to human health and to develop new and innovative solutions to deliver personalized health care. This talk will provide case studies and examples of approaches the newly announced Center for Engineering and Precision Medicine (CEPM) plans to take in order to create new knowledge and enhance its application to improve human health and well-being. Emphasis will be placed on life science entrepreneurship programs and their interface with research and education.

Duration: 30 minutes (1:30-2:00 p.m.)

SPEAKER BIO

Deepak Vashishth, Ph.D.

**Director, Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS),
Professor of Biomedical Engineering, Rensselaer Polytechnic Institute**

Dr. Deepak Vashishth is working to redefine the role of a top-tier research university: one that is engaged in public and private partnerships, involved in interdisciplinary research, and provides quality education — all to drive entrepreneurial, sustainable, and socially responsible scientific discovery and technological innovation.

Through his work as a university center director, previously as a School of Engineering department head, and as a member of professional societies, he has successfully developed partnerships, programs, and platforms to drive translational scientific research across disciplines, sectors, and geographic boundaries. As director of CBIS, he oversees 70 resident and non-resident faculty (from each of the five Rensselaer Polytechnic Institute schools); engages with global partners in the public, private, and academic sectors; and fosters innovative graduate and undergraduate research and education initiatives.



Panel Discussion

“Life Sciences Deal Flow: Solutions to Open the Pipeline”

Overview: In 2021, U.S.-based deal flow into the life sciences reached more than \$45 billion, according to PitchBook, with most capital entering larger markets. This panel will focus on smaller markets and explore solutions that can elevate life science startups in the next five years in these markets, while facilitating greater access to capital.

Moderator: Shreefal Mehta, Ph.D., Chief Commercial Officer, KAYA17

Duration: 45 minutes (2:15-3:00 p.m.)

PANELIST BIOS

Clayton Besch III, Ph.D.

Director, The NYS Innovation Venture Capital Fund (NYSIVCF) at Empire State Development

Clayton L. Besch III is director at The NYS Innovation Venture Capital Fund at Empire State Development (ESD). ESD's NYSIVCF works to bolster the critical capital needs of New York State's innovation economy by providing seed and early-stage venture funding to high-growth startups as they move from concept to commercialization, through early growth and expansion.

With a history of working with Japanese corporations in Japan and the U.S., Dr. Besch has experience in business development, global markets, and early-stage investment. He earned his Ph.D. in agriculture, agriculture operations, and related sciences at The University of Tokyo; his master's degree in fisheries at Nagasaki University; and his bachelor's degree in biology from Hamilton College.



Panel Discussion

“Life Sciences Deal Flow: Solutions to Open the Pipeline”

PANELIST BIOS (CONTINUED)



Noa Conger Simons

President/CEO, Upstate Capital Association of New York

Noa Conger Simons is an entrepreneur, investor, and community builder. She has been the president and CEO of Upstate Capital since 2016, and started the Capital Foundation in 2018. After graduating from Brandeis University, she worked through a private family office as a venture capital investor and executive leader for both nonprofit and for-profit startups through 2015. She has led turnaround management projects, as well as teams doing fundamental research and web platform development. She sourced investment opportunities, conducted due diligence, structured agreements with founders, and managed portfolio investments.

She cofounded the Hudson Valley Startup Fund in 2015 and led day-to-day management through 2019. She leads the NYBPC, New York's intercollegiate business plan competition for emerging entrepreneurs where the focus is on education, equity, inclusion, and launching new ventures. She serves on boards, investment and advisory committees across New York, and independently, as a mentor, advisor, and consultant to select startups and small businesses.



Jon Gordon

Founder & Managing General Partner, HC9 Ventures

Jon Gordon is managing general partner at HC9 Ventures, a venture fund that provides deep health care expertise to emerging health care companies through an engaged LP network of leading health care entrepreneurs and executives. Gordon previously served as senior vice president for innovation at Commonwealth Care Alliance, a non-profit health plan focused on caring for vulnerable populations, and managing director of Winter Street Ventures, its corporate venture arm.

He was simultaneously interim CEO of the Winter Street portfolio Life Pod, a proactive voice-based remote patient monitoring and engagement digital health company. Previously, Gordon founded NYP Ventures, the strategic venture capital arm of New York-Presbyterian. In that role, Gordon led investments in 11 digital health companies, built strategic partnerships with companies such as Walgreens and Zocdoc, and managed the hospital's IP portfolio. Gordon also cofounded the Strategic Venture Group, a collaborative network of more than 20 health system-based venture funds.

Presentation and Discussion

“Connecting Nodes: Accelerating Innovation in Life Sciences”

Overview: Over the last decade, the National Science Foundation has created customer discovery opportunities for scientists and engineers to accelerate the entrepreneurial process through the I-Corps Program. With the success stories that can be found in the collaboration between Rensselaer and Mount Sinai Innovation Partners, hear how the I-Corps process has helped inventors create successful ventures based on their scientific ideas via state and national accelerators.

Moderator: Brian J. Nickerson, Ph.D., Senior Associate Dean for Master’s Programs in the Graduate School of Biomedical Sciences, Mount Sinai Icahn School of Medicine

Duration: 1 hour (3-4 p.m.)

PANELIST BIOS

Joseph Borrello

Engineering Lead & Prototyping Fellow, BioDesign Team, Mount Sinai

A biomedical engineer and Ph.D. candidate at Mount Sinai, Joseph Borrello works in the labs of Doctors Kevin Costa and Junqian Xu, in addition to managing digital fabrication operations within the Sinai BioDesign innovation team and helping run the MSIG and GRO-Biotech student groups. Previously, he’s worked at 3D Systems on technical development in the consumer marketing department and as a liaison with engineering project management teams, in addition to an earlier stint at experiential marketing firm Affinitive.

He received his bachelor’s degree in biomedical engineering from Macaulay Honors College at The City College of New York, and remains active in the Zahn Innovation Center, an on-campus tech startup incubator.

He’s also been involved in several startup ventures in the hardware and biotech spaces. Most recently, he served as the CTO of BioSapien, using advanced manufacturing to create new devices for the treatment of cancer.



Presentation and Discussion

“Connecting Nodes: Accelerating Innovation in Life Sciences”

PANELIST BIOS (CONTINUED)



Craig Cook

Secretary of the Institute and General Counsel, Rensselaer Polytechnic Institute

General Counsel and Secretary of the Institute at Rensselaer Polytechnic Institute Craig Cook serves as the chief legal officer for the Institute, negotiating, writing, and executing agreements and contracts; providing legal counsel to the president and academic and administrative leaders; explaining legal language; and providing legal guidance on domestic and international joint ventures, and strategic partnerships.

Prior to joining Rensselaer, Cook served as an associate general counsel for intellectual property at IBM Corporation, leading a global team of intellectual property attorneys. He has more than 20 years of service with IBM, and has held several global legal leadership roles at IBM. He has worked with IBM’s senior leadership, advising on and managing a broad array of significant legal and compliance matters.

Cook holds a Juris Doctor degree with highest distinction from the College of Law at the University of Iowa, and a Bachelor of Business Administration degree in finance with high distinction from the Tippie College of Business at the University of Iowa.



Eric Ledet, '03 Ph.D.

Chief Science Officer, ReVivo Medical

Dr. Eric Ledet is vice president of research and development and director of the Health Innovation Incubator & Technology Center. Dr. Ledet is a biomedical engineer with 26 years of award-winning translational research experience, 20 years of consulting experience in the medical devices industry, and 10 years of experience as a serial entrepreneur in the medical devices sector. He is also an award-winning educator who has developed curricula and taught courses on design, product development, and technology transfer.

He has served on the medical advisory boards of multiple medical device companies and is chief science officer and cofounder of ReVivo Medical, Inc. He was also cofounder of I/O Surgical, LLC., in Sense Medical, LLC., and Proactive Innovations, LLC. Dr. Ledet has won two SBIR awards and has also served as a reviewer on seven SBIR study sections. He is also an adjunct professor in orthopedic surgery at the Albany Medical College.

Prior to his current role, he was a professor in the Department of Biomedical Engineering at Rensselaer Polytechnic Institute and a research scientist in the Rehabilitation R&D Service at the Stratton VA Medical Center. Dr. Ledet received his bachelor’s degree in mechanical engineering from the University of Arizona and his master’s degree and Ph.D. in biomedical engineering from Rensselaer Polytechnic Institute.

Presentation and Discussion

“Connecting Nodes: Accelerating Innovation in Life Sciences”

PANELIST BIOS (CONTINUED)




Tyree Williams

BioDesign Team, Rensselaer Polytechnic Institute

Tyree Williams is currently a Ph.D. candidate and a member of the core Sinai BioDesign team, which brings together clinicians, designers, engineers, and entrepreneurs from throughout the Mount Sinai Health System to conceptualize, develop, and evaluate groundbreaking medical device technologies.

Williams' team is developing a mortar bone cement system to prevent cement leakage during spinal surgery. The mortar bone cement system actively prevents cement leakage during spine surgery and controls cement curing and enhances adhesion properties. The system allows the team to potentially provide a new treatment approach that also reduces the incidence of secondary fractures at adjacent levels.

Williams was also part of the first cohort of the Rensselaer Polytechnic Institute and Mount Sinai BioDesign Bridge Program, where he started his journey in neurological spine research.



Presentation and Discussion

“Problems to Solution: The Entrepreneurial Process and Navigating Complex Scientific Markets”

Overview: Rensselaer alumni and alumnae have been at the forefront of life sciences innovations, excelling and challenging conventional thinking to solve persistent global challenges, such as invasive bacteria, reliance on plastics, and the delivery of specialized, personal health care. Hear how these alumni and alumnae and prominent regional entrepreneurs found the right markets while identifying problems, solutions, and value propositions that enabled successful commercialization.

Moderator: Jason Nicholas Kuruzovich, Ph.D., Associate Professor and Director, Severino Center for Technological Entrepreneurship, Lally School of Management, Rensselaer Polytechnic Institute

Duration: 1 hour (4:15-5:15 p.m.)

Presentation and Discussion

“Problems to Solution: The Entrepreneurial Process and Navigating Complex Scientific Markets”

PANELIST BIOS



Marc Eigner '97

Executive Partner, Berenson & Company
Former Chief Commercial Officer, H1
Cofounder, Polaris

Marc Eigner is currently an executive partner at Berenson & Company and has more than 20 years of senior leadership experience within the life sciences and technology industries. Most notably, he is the cofounder of Polaris and is known as one of the founding fathers of pharmaceutical commercial compliance technology.

As cofounder of Polaris, Eigner helped to create the largest pharmaceutical commercial compliance technology and services company before selling it to IQVIA in 2017. Over 12 years, Polaris grew to 250 employees with an additional 200 dedicated software developers. Polaris' customer portfolio included: 18 of the top 25 pharma companies, 10 leading biotech companies, and five leading medical device companies. Before that, Eigner served as manager in the technology practice at Accenture.

Eigner received a bachelor's degree in computer systems engineering, a master's degree in computer systems engineering, and an MBA degree from Rensselaer Polytechnic Institute. He also attended the Executive Education Program at the Harvard Business School.

Presentation and Discussion

“Problems to Solution: The Entrepreneurial Process and Navigating Complex Scientific Markets”

PANELIST BIOS (CONTINUED)



Meghan K. Olson '15, M.S. '15

Manager, Mushroom® Packaging | Ecovative Design

Meghan Olson completed a master's degree in mechanical engineering and a dual B.S. in mechanical engineering and design, innovation, and society at Rensselaer Polytechnic Institute and began her career in a fluid system design engineering role at GE Power. Early in her career, she pivoted from engineering to business development with a focus on startups and high-growth companies and has expertise in technical sales, customer experience, product management, process improvement, and systems thinking.

At Ecovative, one of the fastest-growing life sciences companies in New York, she leads the Mushroom® Packaging team, where she is responsible for all commercial activities in North America and supporting the growing global network of MycoComposite™ licensees, with direct oversight over both sales and licensing funnels. Olson is currently focused on overseeing the commissioning of Ecovative's newest Mushroom® Packaging production facility to dramatically increase the company's capability to serve Mushroom® Packaging clients in North America and package products with materials made from the Earth and for the Earth.

Prior to joining Ecovative, she had been an avid fan of the company for more than a decade, ever since being introduced by her late mentor, Burt Swersey, who also mentored Ecovative's founders at RPI and championed the company from day one. She is an engineer with a deep empathy for people, the planet, and the problems that we face – especially issues affecting our health and well-being that are becoming major threats to our society. The late professor instilled her passion to “do well by doing good” and his teachings are woven into everything she does.

Presentation and Discussion

“Problems to Solution: The Entrepreneurial Process and Navigating Complex Scientific Markets”

PANELIST BIOS (CONTINUED)

Sally Temple, Ph.D.

Scientific Director, Principal Investigator, and Cofounder, Neural Stem Cell Institute



Dr. Sally Temple is the scientific director of the Neural Stem Cell Institute, and oversees scientific programs with the goal of understanding the role of neural stem cells in Central Nervous System (CNS) development, maintenance, and repair. A native of York, England, Dr. Temple leads a team of 30 researchers focused on using neural stem cells to develop therapies for eye, brain, and spinal cord disorders. In 2008, she was awarded a MacArthur Fellowship for her contribution and future potential in the neural stem cell field.

Dr. Temple received her undergraduate degree from Cambridge University, Cambridge, UK, specializing in developmental biology and neuroscience. She performed her Ph.D. work in optic nerve development at University College London, UK. She received a Royal Society fellowship to support her postdoctoral work at Columbia University where she focused on spinal cord development.

In 1989, Dr. Temple discovered that the embryonic mammalian brain contained a rare stem cell that could be activated to proliferate in vitro and produce both neurons and glia. Since then, her lab has continued to make pioneering contributions to the field of stem cell research by characterizing neural stem cells and the intrinsic and environmental factors that regulate their behavior. Her lab's research on the characterization of neural stem and progenitors brings us closer to developing effective clinical treatments for central nervous system damage in which tissue is lost, for example, due to neurodegenerative diseases or trauma.

As the scientific director of NSCI, Dr. Temple oversees the research mission from basic to translational projects. Dr. Temple is a member of the board of directors and is a past president of the International Society for Stem Cell Research.

Presentation and Discussion

“Problems to Solution: The Entrepreneurial Process and Navigating Complex Scientific Markets”

PANELIST BIOS (CONTINUED)



Jesse Treu '68, Ph.D.

Founding Partner, Domain Associates

Dr. Jesse Treu was a founding partner of Domain Associates in 1985 and became partner emeritus in 2018. He has been a director of 38 early-stage health care companies, 23 of which have become successful public companies. He has served as a founder, president, and chairman of numerous venture stage companies.

Dr. Treu currently serves on the Board of Trustees of Penn Medicine Princeton Health. He is also a member of the Investment Advisory Board of the Harrington Discovery Institute, a member of the Investment Committee of the American Physical Society, and a member of the RPI Science Leadership Council. He is a former trustee of McCarter Theatre. In 2016, he founded the Stellar Energy Foundation (SEF) and is currently its chairman and CEO. SEF supports research into the development of nuclear fusion energy as an important component of renewable energy.

Prior to the formation of Domain, he was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. He served as president and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Dr. Treu held executive positions at Technicon Instruments (now Siemens Medical Solutions Diagnostics) and at GE. He received his bachelor's degree in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.

Panel Moderator Bios



Jason Nicholas Kuruzovich, Ph.D.

**Associate Professor and Director, Severino Center for Technological Entrepreneurship,
Lally School of Management, Rensselaer Polytechnic Institute**

Dr. Jason Kuruzovich's course on database management integrates the technical challenges of managing data with the business challenges of deriving value through statistical analysis, visualization, and data mining.

His research broadly examines the means through which both individuals and organizations derive value from information systems and focuses on the intersection between information systems and marketing. His research has been published in leading academic journals including the *Journal of Marketing*, *Information Systems Research*, and *Organizational Behavior and Human Decision Processes*. His previous work experience includes consulting experience with numerous Fortune 500 companies and several high-technology startups.



Shreefal Mehta, Ph.D.

Chief Commercial Officer, KAYA17

Dr. Shreefal Mehta helps transform scientific research into successful commercial products. From his early experience in academia, he saw the gap between R&D and useful products and wanted to help take new technologies from the lab to the people that would benefit from these innovative products. Primarily, he is a practical entrepreneur who wants to see good technologies come to good use.

He is cofounder, executive chair, and board member of Pulmokine, a biotech company whose new drug for pulmonary hypertension is now in human clinical trials, successfully demonstrating a public-private model for developing new drugs.

Panel Moderator Bios



Brian J. Nickerson, Ph.D.

Senior Associate Dean for Master's Programs in the Graduate School of Biomedical Sciences, Mount Sinai


Dr. Brian J. Nickerson has over 20 years of multifaceted experience in academic institutions, including 15 years in senior management positions ranging from director, department chair, and academic dean to senior vice president. Dr. Nickerson has launched over 20 successful programs or institutes in his career, many of which were “first-of-its-kind.” He currently serves as the senior associate dean for master’s programs in the Graduate School of Biomedical Sciences, director for the Health Care Delivery Leadership Program, and professor in the Department of Population Health Science and Policy at Mount Sinai. He is responsible for related academic program development and management, digital learning, and academic partnerships.

Dr. Nickerson has been teaching undergraduate and graduate students since 1993 and has produced a large body of visible action research appearing in domestic and international publications and forming the basis for changes in public policy, including health care issues. Moreover, he has been a frequent guest commentator on critical policy and political questions for several media outlets including *The New York Times*, National Public Radio, ABC News, and CBS News, as well as others.

He earned his Ph.D. from the Rockefeller College of the State University of New York at Albany, a Juris Doctor and an MPA from Pace University, and his bachelor’s degree from Iona College.

About Rensselaer Polytechnic Institute

Founded in 1824, Rensselaer Polytechnic Institute is America's first technological research university. Rensselaer encompasses five schools, over 30 research centers, more than 140 academic programs including 25 new programs, and a dynamic community made up of over 6,800 students and over 104,000 living alumni. Rensselaer faculty and alumni include upwards of 155 National Academy members, six members of the National Inventors Hall of Fame, six National Medal of Technology winners, five National Medal of Science winners, and a Nobel Prize winner in Physics. With nearly 200 years of experience advancing scientific and technological knowledge, Rensselaer remains focused on addressing global challenges with a spirit of ingenuity and collaboration. To learn more, please visit www.rpi.edu.



Rensselaer

why not change the world?®